Can DFN-15 Terminate Migraine With Allodynia?
The majority of migraineurs seeking secondary or tertiary medical care develop cutaneous allodynia during the course of migraine, a sensory abnormality mediated by sensitization of central trigeminovascular neurons in the spinal trigeminal nucleus. Triptan therapy can render allodynic migraineurs pain-free within a narrow window of time (20-120 min) that opens with the onset of pain and closes with the establishment of central sensitization. This calls for the development of drugs that can tackle ongoing central sensitization and render allodynic migraineurs pain-free after the window for triptan therapy has expired. There are two main objectives the investigators seek to achieve from this study: to determine whether oral administration of DFN-15 (solution of a COX2 inhibitor, Celecoxib) terminates migraine attacks when given to allodynic participants 3 hours after attack onset; and to determine whether mechanical and heat allodynia that develop during acute migraine attacks could be reversed by late (> 3hrs after attack onset) treatment with DFN-15. Participants will be recruited from the Headache Center and randomized in a double-blinded fashion to receive either the active drug (DFN-15) or placebo in a ratio of 4:1.The participants will be instructed to return to the clinic during a migraine. At the 'during-migraine' visit, which will begin 3 hours after onset of headache, the investigators will document headache intensity, associated symptoms, and mechanical and heat pain threshold (first) before treatment (at 180 min after onset of headache) and (second) at a 120 min after treatment (5 hours after headache onset). Based on our prior experience studying migraine patients, the investigators plan to screen 100 patients to achieve 50 participants completing the 2 study visits as planned. The active drug group will consist of 80/100 patients and 20/100 patients will receive the placebo. The study will be terminated as soon as the first 40 participants who received the DFN-15 and first 10 patients who received placebo completed visit 2.
|Condition or Disease||Intervention/Treatment||Phase|
Arms and Interventions
|Experimental: Active Treatment Group
Oral Solution of 4.8 mL containing 120 mg of DFN-15
|Placebo Comparator: Placebo Group
Oral Solution of 4.8 mL containing 0 mg of DFN-15
Primary Outcome Measures
- Headache Pain Intensity [Up to 6 months]
The proportion of patients demonstrating a decrease in their headache pain intensity is greater than 50% (post-treatment compared to pre-treatment). Pain intensity will be measured with a visual analog scale from 0 (no pain) to 10 (worst pain imaginable).
Secondary Outcome Measures
- Allodynia [Up to 6 months]
The proportion of patients demonstrating allodynia before and after treatment; allodynia to thermal stimuli is defined as pain threshold < 41 degrees Celsius, and to mechanical stimuli as pressure pain threshold of < 30 g.
History of migraine with or without aura for at least 3 years, based on the International Classification of Headache disorders
Two or more migraine attacks per month on average during the year prior to enrollment
Ability to give written consent to enrollment
Fifteen or more headache days per month, on average
Aspirin or NSAID induced asthma or allergy
Any woman who is pregnant or lactacting
History of any of the following: Coronary artery bypass surgery, heart attack, angina, stroke, serious gastrointestinal bleeding, peptic ulcer disease, and/or chronic kidney disease
Medical Conditions requiring the use of diuretics or daily anticoagulants
Severe uncontrolled medical problems or medications that may influence measurements
Contacts and Locations
|1||Hartford HealthCare Headache Center||West Hartford||Connecticut||United States||06107|
Sponsors and Collaborators
- Hartford Hospital
- Rami Burstein, PhD, Beth Israel Deaconess Medical Center
- Dr. Reddy's Laboratories Limited
Study Documents (Full-Text)